Erratum to: Rheumatol Ther (2016) 3:5--29 DOI 10.1007/s40744-016-0031-5 {#Sec1}
=======================================================================

In the original version, the second paragraph (last sentence) of the section "Efficacy of Secukinumab in Patient Subgroups" under heading FUTURE 1 AND FUTURE 2, a value is incorrect. The correct sentence should read as:

The Week 52 observed data were 62.1% for secukinumab 300 mg, 48.3% for secukinumab 150 mg, and 63.2% for secukinumab 75 mg (Fig. 12b).

The online version of the original article can be found under doi:10.1007/s40744-016-0031-5.
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